TherapeuticsMD’s (TXMD) Buy Rating Reaffirmed at Noble Financial

Noble Financial restated their buy rating on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report sent to investors on Thursday.

A number of other equities analysts also recently weighed in on the stock. Cantor Fitzgerald reissued a buy rating and set a $33.00 target price on shares of TherapeuticsMD in a research note on Monday, September 4th. BidaskClub raised shares of TherapeuticsMD from a hold rating to a buy rating in a research note on Friday, September 8th. Morgan Stanley started coverage on shares of TherapeuticsMD in a research note on Friday, September 8th. They set an equal weight rating and a $6.00 target price for the company. Deutsche Bank reissued a buy rating and set a $10.00 target price on shares of TherapeuticsMD in a research note on Wednesday, September 13th. Finally, Jefferies Group reissued a buy rating and set a $15.00 target price on shares of TherapeuticsMD in a research note on Friday, September 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company’s stock. TherapeuticsMD currently has an average rating of Buy and an average target price of $14.50.

Shares of TherapeuticsMD (NASDAQ:TXMD) traded down $0.10 during midday trading on Thursday, reaching $6.20. 3,573,467 shares of the company were exchanged, compared to its average volume of 2,906,673. TherapeuticsMD has a fifty-two week low of $3.50 and a fifty-two week high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last announced its earnings results on Monday, November 6th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The business had revenue of $4.42 million during the quarter, compared to the consensus estimate of $5.36 million. During the same quarter last year, the firm earned ($0.13) earnings per share. TherapeuticsMD’s quarterly revenue was down 19.7% on a year-over-year basis. analysts expect that TherapeuticsMD will post -0.37 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of TXMD. JPMorgan Chase & Co. increased its stake in TherapeuticsMD by 40.4% in the third quarter. JPMorgan Chase & Co. now owns 22,027,855 shares of the company’s stock valued at $112,783,000 after purchasing an additional 6,340,346 shares in the last quarter. Bank of New York Mellon Corp increased its stake in TherapeuticsMD by 13.0% in the third quarter. Bank of New York Mellon Corp now owns 25,877,864 shares of the company’s stock valued at $136,894,000 after purchasing an additional 2,985,846 shares in the last quarter. Stifel Financial Corp increased its stake in TherapeuticsMD by 377.9% in the second quarter. Stifel Financial Corp now owns 2,052,030 shares of the company’s stock valued at $10,820,000 after purchasing an additional 1,622,668 shares in the last quarter. Voya Investment Management LLC increased its stake in TherapeuticsMD by 33.4% in the second quarter. Voya Investment Management LLC now owns 2,959,107 shares of the company’s stock valued at $15,595,000 after purchasing an additional 741,588 shares in the last quarter. Finally, State Street Corp increased its stake in TherapeuticsMD by 14.9% in the second quarter. State Street Corp now owns 4,486,585 shares of the company’s stock valued at $23,647,000 after purchasing an additional 583,094 shares in the last quarter. 73.72% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “TherapeuticsMD’s (TXMD) Buy Rating Reaffirmed at Noble Financial” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/10/therapeuticsmds-txmd-buy-rating-reaffirmed-at-noble-financial.html.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply